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Introduction
The full power of immune system, leads to the 
elimination of cancerous tumour cells and prevents 
the development of malignancy. Tumour cells 
express immunogenic peptides, due to mutation 
which are recognised as foreign by T-cell and B-cells.
However cancer cells can develop mechanisms to 
escape immune elimination (Hanahan & Weinberg 
2011) such as HLA down regulation which can limit 
peptide expression and decrease immunogenicity
and upregulation of PD-L1 which inhibit the action of 
T-cells, B-cells and macrophages.
Hypothesis
It was hypothesized PD-L1 and HLA-1 are 
upregulated in lung cancer cell lines (H838, H838-
EGFR, A549, A549-ALK, NCI 1650, HCC 827, TWIT 
& JACKET) and can be modulated by IFN-γ
Aims
The aim of this study was to quantify the percent 
expression of PD-L1 and HLA-1 in lung cancer cell 
lines in the presence and absence of IFN-γ.
Methods
Results
Figure 2: Representative flow cytometric gating strategies used for 
PD-L1 analysis in cell lines H838, H838-EGFR, A549, A549-ALK, 
TWIT, JACKET, HCC 827 and NCI 1650 respectively.
Figure 3A: Mean and SD of PD-L1 cell percentage expression across 
lung cancer cell lines varies in the absence of IFN-γ. n=3 for 
independent repeats. 3B: Median fluorescent intensity (MFI) of PD-L1 
expression
NCI 1650, JACKET and HCC 827 present with high PD-L1 expression. 
H838, H838-EGFR and A549 express a more moderate percentage of 
PD-L1 whilst TWIT and A549-ALK have a low level of PD-L1 
expression
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Figure 1: PD-L1/PD-1 binding inhibits T-cell killing of 
tumour cell (NCI/Winslow 2015).
Materials
Media used: DMEM (Gibco) supplemented with 10% fetal calf 
serum and 1% Penicillin-streptomycin. RPMI (Gibco) 
supplemented with 10% fetal calf serum and 1% Penicillin-
streptomycin. 50:50 mix of the WIT-P medium and Wit-T 
(Cellaria). Renaissance medium (RETM) (Cellaria) with 4% 
Hyclone serum and 3% RETM supplement.
Antibodies: APC anti-human CD274 (B7-H1, PD-L1) antibody 
(Biolegend). APC Mouse IgG2b, κ Isotype Control Antibody 
(Biolegend). FITC Mouse Anti-Human HLA-ABC (BD 
bioscience). FITC Mouse IgG1, κ Isotype Control (BD 
bioscience). 
Recombinant Human IFN-γ (carrier-free) (Biolegend)
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Figure 5A: HLA-1 cell percentage expression in unstimulated lung 
cancer cell lines. levels. 5B: MFI of HLA-1 expression
H838-EGFR, HCC 827 present with high HLA expression whilst TWIT, 
JACKET, A549 and A549-ALK cell lines express HLA-1 at lower levels
Figure 6: Optimisation of IFN-γ to find the concentration which would 
maximise PD-L1 upregulation compared to untreated controls.  
10ng/mL was determined as the optimum due to the plateauing after 
10ng/mL  
Modulating cell surface antigens with IFN-γ
A
Figure 7A: IFN-γ stimulation of cell line HCC 827. HLA-1 has been 
upregulated by IFN-γ. Following a student T test statistical analysis it was 
revealed that there was no significant difference between IFN-γ treated 
and untreated HLA-1 expression. 7B: The effect of IFN-γ viability of HCC 
827 cells.
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Figure 4: Flow cytometric gating strategies used for HLA-1 analysis of cell 
lines H838-EGFR, TWIT, JACKETS,  HCC 827, A549-ALK and A549 
respectively.
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Conclusion & future work
• IFN-y increases PD-L1 expression 
• Treat all cell lines with IFN-γ with repeats 
• Assess the effect of IFN-γ on cell viability for all cell lines 
• Treat cell lines with a combination of IFN-γ and TNF-α
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